Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.Ruxolitinib ...
DelveInsight's analysis indicates a promising outlook for the dry eye disease market from 2024 to 2034, with positive growth anticipated. This growth trajectory is attributed to the emergence ...